Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gemfibrozil--a new lipid lowering agent.

D T Nash

    Journal of Medicine
    |January 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Gemfibrozil and clofibrate effectively manage hyperlipidemia. This study compared their efficacy in patients with type II and IV hyperlipidemia, noting significant effects in responders.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Diabetes mellitus and cardiovascular disease.

    The Diabetes educator·2002
    Same author

    Effectiveness of medical therapy alone compared with coronary angioplasty or left internal mammary artery bypass for single-vessel coronary artery disease.

    The American journal of cardiology·2001
    Same author

    Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.

    Archives of internal medicine·2000
    Same author

    Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events.

    Journal of the American College of Cardiology·1999
    Same author

    Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

    Circulation·1998
    Same author

    A conversation between two cardiologists.

    The American journal of cardiology·1996

    Area of Science:

    • Cardiology
    • Pharmacology
    • Metabolic Disorders

    Background:

    • Hyperlipidemia, specifically types II and IV, presents a significant cardiovascular risk.
    • Current pharmacological interventions aim to normalize lipid profiles and mitigate associated risks.

    Purpose of the Study:

    • To compare the efficacy of gemfibrozil and clofibrate in treating type II and IV hyperlipidemia.
    • To evaluate drug responses in the overall patient population and identify responders.

    Main Methods:

    • A double-blind, cross-over study design was employed.
    • Thirty patients with type II and IV hyperlipidemia participated.
    • Gemfibrozil (1200 mg and 1600 mg daily) was compared against clofibrate (2000 mg daily).

    Main Results:

    Related Experiment Videos

    • Both gemfibrozil and clofibrate demonstrated effects on lipid profiles.
    • The study analyzed outcomes for the entire cohort and specifically for patient subgroups who responded to treatment.

    Conclusions:

    • Gemfibrozil and clofibrate are viable therapeutic options for managing type II and IV hyperlipidemia.
    • Individual patient response is a critical factor in assessing treatment effectiveness.